Tiziana Granata

List of Publications by Year
in descending order

174	10,753	41627	40945
papers	citations	51 h-index	97 g-index

177	177	177	10446
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inflammation in pediatric epilepsies: Update on clinical features and treatment options. Epilepsy and Behavior, 2022, 131, 107959.	0.9	6
2	Psychiatric autoimmune conditions in children and adolescents: Is catatonia a severity marker?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110028.	2.5	11
3	Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome. Neurology, 2021, 96, e1319-e1333.	1.5	6
4	Autoantibodies, Encephalopathies, and Epilepsy. Agents and Actions Supplements, 2021, , 125-147.	0.2	0
5	A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies. Epilepsia Open, 2021, 6, 160-170.	1.3	3
6	Multicenter prospective longitudinal study in 34 patients with Dravet syndrome: Neuropsychological development in the first six years of life. Brain and Development, 2021, 43, 419-430.	0.6	7
7	Focal status and acute encephalopathy in a 13-year-old boy with de novo DNM1L mutation: Video-polygraphic pattern and clues for differential diagnosis. Brain and Development, 2021, 43, 644-651.	0.6	5
8	Severe epilepsy in CNTNAP2-related Pitt-Hopkins-like syndrome successfully treated with stiripentol. Seizure: the Journal of the British Epilepsy Association, 2021, 88, 143-145.	0.9	4
9	Cortico-muscular and cortico-cortical coherence changes resulting from Perampanel treatment in patients with cortical myoclonus. Clinical Neurophysiology, 2021, 132, 1057-1063.	0.7	6
10	Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. American Journal of Human Genetics, 2021, 108, 965-982.	2.6	35
11	Do the functional properties of HCN1 mutants correlate with the clinical features in epileptic patients?. Progress in Biophysics and Molecular Biology, 2021, 166, 147-155.	1.4	11
12	Letter to the Editor Regarding the Article â€œWhole-Exome Sequencing in NF1-Related West's Syndrome Leads to the Identification of KCNC2 as a Novel Candidate Gene for Epilepsyâ€• Neuropediatrics, 2021, 52, 153-153.	0.3	0
13	Progressive Myoclonus Epilepsies. Neurology: Genetics, 2021, 7, e641.	0.9	20
14	Different circuitry dysfunction in drug-naive patients with juvenile myoclonic epilepsy and juvenile absence epilepsy. Epilepsy and Behavior, 2021, 125, 108443.	0.9	0
15	Trends in pediatric epilepsy surgery in Europe between 2008 and 2015: Countryâ€• centerâ€• and ageâ€•specific variation. Epilepsia, 2020, 61, 216-227.	2.6	44
16	Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene. Epilepsia, 2020, 61, 2474-2485.	2.6	31
17	Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy. Pharmacological Research, 2020, 160, 105200.	3.1	7
18	Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A realâ€•world study. Epilepsia, 2020, 61, 2405-2414.	2.6	37

#	Article	IF	Citations
19	Did the COVIDâ€19 pandemic silence the needs of people with epilepsy?. Epileptic Disorders, 2020, 22, 439-442.	0.7	46
20	Cardiac phenotype in ATP1A3 -related syndromes. Neurology, 2020, 95, e2866-e2879.	1.5	19
21	Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2467-2474.	1.7	80
22	SCN8A splicing mutation causing skipping of the exon 15 associated with intellectual disability and cortical myoclonus. Seizure: the Journal of the British Epilepsy Association, 2020, 82, 56-58.	0.9	0
23	Epilepsy and NREM-parasomnia caused by novel hemizygous ARHGEF9 mutation. Sleep Medicine, 2020, 76, 158-159.	0.8	2
24	Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17â€‰458 subjects. Brain, 2020, 143, 2106-2118.	3.7	47
25	A de novo heterozygous mutation in KCNC2 gene implicated in severe developmental and epileptic encephalopathy. European Journal of Medical Genetics, 2020, 63, 103848.	0.7	24
26	White matter and cerebellar involvement in alternating hemiplegia of childhood. Journal of Neurology, 2020, 267, 1300-1311.	1.8	10
27	Early Parkinsonism in a Senegalese girl with Lafora disease. Epileptic Disorders, 2020, 22, 233-236.	0.7	4
28	Immunotherapy in GRIN2A-negative Landau-Kleffner Syndrome. Minerva Pediatrica, 2020, 72, 139-141.	2.6	1
29	TheÂMovement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 724-726.	0.9	71
30	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	2.6	237
31	Polygenic burden in focal and generalized epilepsies. Brain, 2019, 142, 3473-3481.	3.7	90
32	Gait abnormalities in people with Dravet syndrome: A cross-sectional multi-center study. European Journal of Paediatric Neurology, 2019, 23, 808-818.	0.7	16
33	Early clinical and EEG findings associated with the outcome in childhood absence epilepsy. Epilepsy and Behavior, 2019, 98, 273-278.	0.9	12
34	An Italian multicentre study of perampanel in progressive myoclonus epilepsies. Epilepsy Research, 2019, 156, 106191.	0.8	19
35	Progressive myoclonus epilepsy caused by a gain-of-function KCNA2 mutation. Seizure: the Journal of the British Epilepsy Association, 2019, 65, 106-108.	0.9	16
36	Relapse risk factors in antiâ€Nâ€methylâ€Dâ€aspartate receptor encephalitis. Developmental Medicine and Child Neurology, 2019, 61, 1101-1107.	1.1	40

#	Article	IF	Citations
37	Epileptic phenotypes in children with earlyâ€onset mitochondrial diseases. Acta Neurologica Scandinavica, 2019, 140, 184-193.	1.0	15
38	Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes. Journal of Neurology, 2019, 266, 1439-1448.	1.8	18
39	HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature. Epilepsy Research, 2019, 153, 49-58.	0.8	32
40	Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2019, 394, 2243-2254.	6.3	227
41	Dravet syndrome: Early electroclinical findings and longâ€term outcome in adolescents and adults. Epilepsia, 2019, 60, S49-S58.	2.6	20
42	Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP2-Dependent K+ Channel Gating. Molecular Neurobiology, 2018, 55, 7009-7024.	1.9	21
43	Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. European Journal of Paediatric Neurology, 2018, 22, 301-307.	0.7	34
44	Electroclinical findings and long-term outcomes in epileptic patients with inv dup (15). Acta Neurologica Scandinavica, 2018, 137, 575-581.	1.0	11
45	A causality algorithm to guide diagnosis and treatment of catatonia due to autoimmune conditions in children and adolescents. Schizophrenia Research, 2018, 200, 68-76.	1.1	19
46	Defining the electroclinical phenotype and outcome of PCDH19â€related epilepsy: A multicenter study. Epilepsia, 2018, 59, 2260-2271.	2.6	39
47	HCN1mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond. Brain, 2018, 141, 3160-3178.	3.7	96
48	A novel de novo HCN1 loss-of-function mutation in genetic generalized epilepsy causing increased neuronal excitability. Neurobiology of Disease, 2018, 118, 55-63.	2.1	47
49	Encephalopathies with intracranial calcification in children: clinical and genetic characterization. Orphanet Journal of Rare Diseases, 2018, 13, 135.	1.2	17
50	The noncoding RNA AK127244 in 2p16.3 locus: A new susceptibility region for neuropsychiatric disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 557-562.	1.1	4
51	A Loss-of-Function HCN4 Mutation Associated With Familial Benign Myoclonic Epilepsy in Infancy Causes Increased Neuronal Excitability. Frontiers in Molecular Neuroscience, 2018, 11, 269.	1.4	25
52	Electroclinical features of epilepsy monosomy 1p36 syndrome and their implications. Acta Neurologica Scandinavica, 2018, 138, 523-530.	1.0	8
53	Movement-activated cortical myoclonus in Dravet syndrome. Epilepsy Research, 2017, 130, 47-52.	0.8	12
54	Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology, 2017, 88, 1037-1044.	1.5	93

#	Article	IF	Citations
55	Alternating Hemiplegia and Epilepsia Partialis Continua: A new phenotype for a novel compound TBC1D24 mutation. Seizure: the Journal of the British Epilepsy Association, 2017, 47, 71-73.	0.9	16
56	Outcome of childhood-onset epilepsy from adolescence to adulthood: Transition issues. Epilepsy and Behavior, 2017, 69, 161-169.	0.9	41
57	FCD Type II and mTOR pathway: Evidence for different mechanisms involved in the pathogenesis of dysmorphic neurons. Epilepsy Research, 2017, 129, 146-156.	0.8	21
58	Variable course of Unverricht-Lundborg disease. Neurology, 2017, 89, 1691-1697.	1.5	18
59	Epileptic spikes in Rasmussenâ€™s encephalitis: Migratory pattern and short-term evolution. A MEG study. Clinical Neurophysiology, 2017, 128, 1898-1905.	0.7	2
60	Perisylvian, including insular, childhood epilepsy: Presurgical workup and surgical outcome. Epilepsia, 2017, 58, 1360-1369.	2.6	51
61	Rasmussen encephalitis tissue transfer program. Epilepsia, 2016, 57, 1005-1007.	2.6	3
62	6.157 A NEW CAUSALITY ALGORITHM TO ENHANCE DIAGNOSIS AND TREATMENT OF CATATONIA DUE TO AUTOIMMUNE CONDITIONS IN CHILDREN AND ADOLESCENTS. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S254.	0.3	0
63	Symptomatic and presumed symptomatic focal epilepsies in childhood: An observational, prospective multicentre study. Epilepsia, 2016, 57, 1808-1816.	2.6	9
64	Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis. Journal of Neurology, 2016, 263, 765-771.	1.8	38
65	Small 6q16.1 Deletions Encompassing POU3F2 Cause Susceptibility to Obesity and Variable Developmental Delay with Intellectual Disability. American Journal of Human Genetics, 2016, 98, 363-372.	2.6	36
66	Clinical and genetic features of paroxysmal kinesigenic dyskinesia in Italian patients. European Journal of Paediatric Neurology, 2016, 20, 152-157.	0.7	14
67	Clinical profile of patients with ATP1A3 mutations in Alternating Hemiplegia of Childhoodâ€”a study of 155 patients. Orphanet Journal of Rare Diseases, 2015, 10, 123.	1.2	117
68	Pathophysiology of Brain Tumor-Related Epilepsy. , 2015, , 111-118.		1
69	Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. Brain, 2015, 138, 2859-2874.	3.7	30
70	Focal seizures versus epileptic spasms in children with focal cortical dysplasia and epilepsy onset in the first year. Epilepsy Research, 2015, 109, 203-209.	0.8	8
71	Electroencephalographic (EEG) Photoparoxysmal Responses Under 5 Years of Age. Journal of Child Neurology, 2015, 30, 1824-1830.	0.7	12
72	Focal seizure, focal dyskinesia, or both? A complex motor phenomenon reveals anti-NMDAR encephalitis. Seizure: the Journal of the British Epilepsy Association, 2015, 27, 16-18.	0.9	13

#	Article	IF	Citations
73	Mitochondrial Complex III Deficiency Caused by TTC19 Defects: Report of a Novel Mutation and Review of Literature. JIMD Reports, 2015, 22, 115-120.	0.7	15
74	Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations. Neurology, 2015, 85, 316-324.	1.5	40
75	Refractory Absence Epilepsy and Glut1 Deficiency Syndrome: A New Case Report and Literature Review. Neuropediatrics, 2014, 45, 328-332.	0.3	22
76	Transition into adulthood: Tuberous sclerosis complex, <scp>S</scp>turgeâ€<scp>W</scp>eber syndrome, and <scp>R</scp>asmussen encephalitis. Epilepsia, 2014, 55, 29-33.	2.6	32
77	VARS2andTARS2Mutations in Patients with Mitochondrial Encephalomyopathies. Human Mutation, 2014, 35, 983-989.	1.1	86
78	Inflammatory pathways of seizure disorders. Trends in Neurosciences, 2014, 37, 55-65.	4.2	196
79	Longâ€term outcome after limited cortical resections in two cases of adultâ€onset Rasmussen encephalitis. Epilepsia, 2014, 55, e38-e43.	2.6	18
80	Hemispherotomy in Rasmussen encephalitis: Long-term outcome in an Italian series of 16 patients. Epilepsy Research, 2014, 108, 1106-1119.	0.8	41
81	A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia, 2013, 54, 30-32.	2.6	51
82	Impaired surface Î±Î²Î³ GABAA receptor expression in familial epilepsy due to a GABRG2 frameshift mutation. Neurobiology of Disease, 2013, 50, 135-141.	2.1	27
83	Vagus nerve stimulation for drug-resistant Epilepsia Partialis Continua: Report of four cases. Epilepsy Research, 2013, 107, 163-171.	0.8	20
84	Reflex myoclonic epilepsy in infancy: A multicenter clinical study. Epilepsy Research, 2013, 103, 237-244.	0.8	8
85	Electroclinical Features and Long-Term Outcome of Cryptogenic Epilepsy in Children with Down Syndrome. Journal of Pediatrics, 2013, 163, 1754-1758.	0.9	25
86	Rasmussen encephalitis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 111, 511-519.	1.0	158
87	Overview of presurgical assessment and surgical treatment of epilepsy from the Italian League Against Epilepsy. Epilepsia, 2013, 54, 35-48.	2.6	45
88	The blood-brain barrier hypothesis in drug resistant epilepsy. Brain, 2012, 135, e211-e211.	3.7	22
89	Epilepsy and NREM-parasomnia: A complex and reciprocal relationship. Sleep Medicine, 2012, 13, 442-444.	0.8	12
90	Bloodâ€“brain barrier dysfunction and epilepsy: Pathophysiologic role and therapeutic approaches. Epilepsia, 2012, 53, 1877-1886.	2.6	199

#	Article	IF	Citations
91	Focal seizures with affective symptoms are a major feature of PCDH19 geneâ€“related epilepsy. Epilepsia, 2012, 53, 2111-2119.	2.6	63
92	Metabolic and degenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 108, 485-511.	1.0	5
93	De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nature Genetics, 2012, 44, 1030-1034.	9.4	345
94	Early add-on immunoglobulin administration in Rasmussen encephalitis: The hypothesis of neuroimmunomodulation. Medical Hypotheses, 2011, 77, 917-920.	0.8	7
95	Efficacy of Anti-Inflammatory Therapy in a Model of Acute Seizures and in a Population of Pediatric Drug Resistant Epileptics. PLoS ONE, 2011, 6, e18200.	1.1	130
96	Cognitive development in Dravet syndrome: A retrospective, multicenter study of 26 patients. Epilepsia, 2011, 52, 386-392.	2.6	99
97	Clinical course and variability of non-Rasmussen, nonstroke motor and sensory epilepsia partialis continua: A European survey and analysis of 65 cases. Epilepsia, 2011, 52, 1168-1176.	2.6	50
98	Comprehensive care of children with Dravet syndrome. Epilepsia, 2011, 52, 90-94.	2.6	12
99	Immuneâ€mediated epilepsies. Epilepsia, 2011, 52, 5-11.	2.6	76
100	Scurvy hidden behind neuropsychiatric symptoms. Neurological Sciences, 2011, 32, 1091-1093.	0.9	16
101	Epilepsy in type 1 Chiari malformation. Neurological Sciences, 2011, 32, 303-306.	0.9	21
102	Association of intronic variants of the KCNAB1 gene with lateral temporal epilepsy. Epilepsy Research, 2011, 94, 110-116.	0.8	9
103	The Etiological Role of Blood-Brain Barrier Dysfunction in Seizure Disorders. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-9.	0.8	58
104	West syndrome associated with 14q12 duplications harboring FOXG1. Neurology, 2011, 76, 1600-1602.	1.5	49
105	Dravet syndrome: Early clinical manifestations and cognitive outcome in 37 Italian patients. Brain and Development, 2010, 32, 71-77.	0.6	94
106	Hemispherotomy and functional hemispherectomy: Indications and outcome. Epilepsy Research, 2010, 89, 104-112.	0.8	115
107	Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy. Epilepsia, 2010, 51, 647-654.	2.6	60
108	Transporters in Drug-Refractory Epilepsy: Clinical Significance. Clinical Pharmacology and Therapeutics, 2010, 87, 13-15.	2.3	35

#	Article	IF	Citations
109	Factors Modulating Seizure Susceptibility. , 2010, , 193-201.		0
110	Rasmussen's Encephalitis. Blue Books of Neurology, 2009, , 161-176.	0.1	0
111	Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiology of Disease, 2009, 33, 171-181.	2.1	270
112	Joubert syndrome with bilateral polymicrogyria: Clinical and neuropathological findings in two brothers. American Journal of Medical Genetics, Part A, 2009, 149A, 1511-1515.	0.7	22
113	Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6. Biochemical and Biophysical Research Communications, 2009, 379, 892-897.	1.0	45
114	Management of the patient with medically refractory epilepsy. Expert Review of Neurotherapeutics, 2009, 9, 1791-1802.	1.4	72
115	An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology, 2007, 69, 250-254.	1.5	115
116	Revelation of a Novel CLN5 Mutation in Early Juvenile Neuronal Ceroid Lipofuscinosis. Neuropediatrics, 2007, 38, 46-49.	0.3	41
117	Intellectual and language findings and their relationship to EEG characteristics in benign childhood epilepsy with centrotemporal spikes. Epilepsy and Behavior, 2007, 10, 278-285.	0.9	113
118	Periventricular nodular heterotopia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 177-189.	1.0	9
119	Schizencephaly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 235-246.	1.0	4
120	Seizure-Promoting Effect of Blood?Brain Barrier Disruption. Epilepsia, 2007, 48, 732-742.	2.6	442
121	Brain MRI Findings in Severe Myoclonic Epilepsy in Infancy and Genotype?Phenotype Correlations. Epilepsia, 2007, 48, 1092-1096.	2.6	89
122	ICTAL EEG Fast Activity in West Syndrome: From Onset to Outcome. Epilepsia, 2007, 48, 2101-2110.	2.6	20
123	Somatic and germline mosaicisms in Severe Myoclonic Epilepsy of Infancy. Biochemical and Biophysical Research Communications, 2006, 341, 489-493.	1.0	102
124	Periventricular Nodular Heterotopia: Classification, Epileptic History, and Genesis of Epileptic Discharges. Epilepsia, 2006, 47, 86-97.	2.6	150
125	Suppressive Efficacy by a Commercially Available Blue Lens on PPR in 610 Photosensitive Epilepsy Patients. Epilepsia, 2006, 47, 529-533.	2.6	96
126	Familial Occurrence of Febrile Seizures and Epilepsy in Severe Myoclonic Epilepsy of Infancy (SMEI) Patients with SCN1A Mutations. Epilepsia, 2006, 47, 1629-1635.	2.6	48

#	Article	IF	Citations
127	Adult-Onset Rasmussen's Encephalitis: Anatomical-Electrographic-Clinical Features of 7 Italian Cases. Epilepsia, 2006, 47, 41-46.	2.6	108
128	Polymicrogyria and deletion 22q11.2 syndrome: Window to the etiology of a common cortical malformation. American Journal of Medical Genetics, Part A, 2006, 140A, 2416-2425.	0.7	125
129	Brain Inflammation in Epilepsy: Experimental and Clinical Evidence. Epilepsia, 2005, 46, 1724-1743.	2.6	921
130	Topical Review: Schizencephaly: Clinical Spectrum, Epilepsy, and Pathogenesis. Journal of Child Neurology, 2005, 20, 313-318.	0.7	92
131	Electroencephalographic Recordings of Focal Seizures in Patients Affected by Periventricular Nodular Heterotopia: Role of the Heterotopic Nodules in the Genesis of Epileptic Discharges. Journal of Child Neurology, 2005, 20, 369-377.	0.7	24
132	Serial electrophysiological studies of the visual pathway in patients treated with vigabatrin. International Congress Series, 2005, 1278, 41-44.	0.2	5
133	Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement. Brain, 2005, 128, 454-471.	3.7	490
134	Topical Review: Schizencephaly: Clinical Spectrum, Epilepsy, and Pathogenesis. Journal of Child Neurology, 2004, 19, 313-318.	0.7	12
135	Subcortical nodular heterotopia: a functional MRI and somatosensory evoked potentials study. Neurological Sciences, 2004, 25, 225-229.	0.9	15
136	Diagnostic imaging in 13Âcases of Rasmussen's encephalitis: can early MRI suggest the diagnosis?. Neuroradiology, 2003, 45, 171-183.	1.1	116
137	Rasmussen?s syndrome. Neurological Sciences, 2003, 24, s239-s243.	0.9	43
138	No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancy. Epilepsy Research, 2003, 53, 196-200.	0.8	20
139	Epileptic and imaging findings in perinatal hypoxic-ischemic encephalopathy with ulegyria. Epilepsy Research, 2003, 55, 235-243.	0.8	45
140	Rasmussenâ€™s encephalitis. Neurology, 2003, 60, 422-425.	1.5	137
141	Paroxysmal dyskinesias in childhood. Pediatric Neurology, 2003, 28, 168-172.	1.0	27
142	Experience with immunomodulatory treatments in Rasmussenâ€™s encephalitis. Neurology, 2003, 61, 1807-1810.	1.5	161
143	Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology, 2003, 60, 1961-1967.	1.5	241
144	Rasmussenâ€™s encephalitis: update on pathogenesis and treatment. Expert Review of Neurotherapeutics, 2003, 3, 835-843.	1.4	3

#	Article	IF	Citations
145	Similar binding to glutamate receptors by Rasmussen and partial epilepsy patientsâ€™ sera. Neurology, 2002, 59, 1998-2001.	1.5	25
146	Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. Journal of Neuroimmunology, 2002, 131, 179-185.	1.1	151
147	Single-Dose Pharmacokinetics of Lamotrigine in Children: Influence of Age and Antiepileptic Comedication. Therapeutic Drug Monitoring, 2001, 23, 217-222.	1.0	31
148	Positive response to immunomodulatory therapy in an adult patient with Rasmussenâ€™s encephalitis. Neurology, 2001, 56, 248-250.	1.5	74
149	Epileptic phenotypes associated with mitochondrial disorders. Neurology, 2001, 56, 1340-1346.	1.5	143
150	Labeling of rat neurons by anti-GluR3 IgG from patients with Rasmussen encephalitis. Neurology, 2001, 57, 324-327.	1.5	25
151	Neuromuscular syndrome associated with the 3291Tâ†'C mutation of mitochondrial DNA: a second case. Neuromuscular Disorders, 2000, 10, 415-418.	0.3	15
152	Congenital malformations due to antiepileptic drugs. Epilepsy Research, 1999, 33, 145-158.	0.8	351
153	Malformations in Offspring of Women with Epilepsy: A Prospective Study. Epilepsia, 1999, 40, 1231-1236.	2.6	181
154	Spectral properties of EEG fast activity ictal discharges associated with infantile spasms. Clinical Neurophysiology, 1999, 110, 593-603.	0.7	34
155	Long-term selective IgG immunoadsorption improves Rasmussen's encephalitis. Neurology, 1998, 51, 302-305.	1.5	106
156	Partial Seizures Associated with Antiphospholipid Antibodies in Childhood. Neuropediatrics, 1998, 29, 249-254.	0.3	41
157	Familial schizencephaly associated with EMX2 mutation. Neurology, 1997, 48, 1403-1406.	1.5	145
158	The Contribution of Tertiary Centers to the Quality of the Diagnosis and Treatment of Epilepsy. Epilepsia, 1997, 38, 1338-1343.	2.6	14
159	Periventricular Nodular Heterotopia: Epileptogenic Findings. Epilepsia, 1997, 38, 1173-1182.	2.6	66
160	Lamotrigine Plasma Concentrations in Children and Adults. Therapeutic Drug Monitoring, 1997, 19, 620-627.	1.0	40
161	A Number of Schizencephaly Patients Including 2 Brothers Are Heterozygous for Germline Mutations in the Homeobox Gene EMX2. European Journal of Human Genetics, 1997, 5, 186-190.	1.4	66
162	Schizencephaly: Neuroradiologic and Epileptologic Findings. Epilepsia, 1996, 37, 1185-1193.	2.6	63

#	Article	IF	Citations
163	ILAE Classification of Epilepsies: Its Applicability and Practical Value of Different Diagnostic Categories. Epilepsia, 1996, 37, 1051-1059.	2.6	49
164	Neuronal migration disorders and epilepsy: a morphological analysis of three surgically treated patients. Epilepsy Research, 1996, 26, 49-58.	0.8	51
165	Linguistic Development in a Patient with Landau-Kleffner Syndrome: A Nine-Year Follow-Up. Neuropediatrics, 1995, 26, 19-25.	0.3	18
166	Double cortex syndrome: Electroclinical study of three cases. Italian Journal of Neurological Sciences, 1994, 15, 15-23.	0.1	11
167	Band heterotopia: Correlation of outcome with magnetic resonance imaging parameters. Annals of Neurology, 1994, 36, 609-617.	2.8	206
168	Lamotrigine in Resistant Childhood Epilepsy. Neuropediatrics, 1993, 24, 332-336.	0.3	35
169	Comparative Pharmacokinetic Study of Chewable and Conventional Carbamazepine in Children. Epilepsia, 1993, 34, 158-160.	2.6	16
170	Burst Suppression and Impairment of Neocortical Ontogenesis: Electroclinical and Neuropathologic Findings in Two Infants with Early Myoclonic Encephalopathy. Epilepsia, 1993, 34, 800-808.	2.6	36
171	Changes in Unbound and Total Valproic Acid Concentrations After Replacement of Carbamazepine with Oxcarbazepine. Therapeutic Drug Monitoring, 1992, 14, 376-379.	1.0	41
172	Intrauterine growth in the offspring of epileptic mothers. Acta Neurologica Scandinavica, 1992, 86, 555-557.	1.0	34
173	Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica, 1992, 85, 204-207.	1.0	63
174	Functional Characterization of Two Variants at the Intron 6â€”Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes. Frontiers in Pharmacology, 0, 13, .	1.6	0